NASDAQ$ALKS
Alkermes plc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Alkermes reported financial results for the fourth quarter and year ended December 31, 2022.
Alkermes plc reported Q4 2022 financial results, with total revenues of $304.7 million compared to $324.5 million for the same period in the prior year. GAAP net loss was $28.3 million, or a loss of $0.17 per share, while non-GAAP net income was $24.2 million, or $0.14 per share.
- Total revenues for the quarter were $304.7 million, compared to $324.5 million for the same period in the prior year.
- Net sales of proprietary products for the quarter were $216.1 million, compared to $178.9 million for the same period in the prior year.
- GAAP net loss for the quarter was $28.3 million, or a basic and diluted GAAP loss per share of $0.17.
- Non-GAAP net income for the quarter was $24.2 million, or a non-GAAP diluted earnings per share of $0.14.
Headline financials
Revenue & EPS history
Alkermes · Revenue · Quarterly
$305M
Revenue by segment
Alkermes · $216M total across 3 segments · Q4 2022
- VIVITROL$102M+10.8%47.2%
- ARISTADA$79.2M+0.7%36.6%
- LYBALVI$34.9M+324.8%16.1%
Forward guidance
The company provided financial expectations for 2023, reflecting the combined neuroscience and oncology business for the full year, anticipating continued growth of proprietary products and investment in a direct-to-consumer campaign to support the launch of LYBALVI.
Tailwinds
- Total Revenue $1,130 – $1,250 million
- VIVITROL Net Sales $380 – $410 million
- ARISTADA Net Sales $315 – $345 million
- LYBALVI Net Sales $180 – $205 million
- INVEGA Franchise Royalties $25 – $30 million
Headwinds
- GAAP Net Loss ($160) – ($200) million
- GAAP Net Loss per Share ($0.96) – ($1.20)
- Non-GAAP Net Income $0 – $40 million
- Non-GAAP Net Earnings Per Share (Diluted) $0.00 – $0.23
- Capital Expenditures $35 – $40 million
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
-0.6%
Avg return
Earnings day
-0.0%
Avg return
5 days after
-0.5%
Avg return
30 days after
45%
27 / 60 earnings
Positive
+16.6%
Q4 2017
Best reaction
-14.8%
Q1 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.2% | +2.5% | +27.0% | |
| Q4 2025 | -6.6% | -9.4% | -12.0% | |
| Q3 2025 | +3.9% | +3.3% | +0.0% | |
| Q1 2025 | +6.3% | +5.5% | +6.4% | |
| Q4 2024 | +4.8% | +12.3% | +6.5% | |
| Q3 2024 | -6.3% | -5.1% | +3.3% | |
| Q2 2024 | +12.2% | +11.7% | +11.8% | |
| Q1 2024 | -2.8% | -1.8% | -4.6% | |
| Q4 2023 | +15.0% | +8.6% | +2.7% | |
| Q3 2023 | -2.4% | -4.0% | -3.7% | |
| Q2 2023 | -1.8% | -5.1% | -11.9% | |
| Q1 2023 | -7.1% | -6.1% | -3.9% | |
| Q4 2022 | +4.0% | +2.9% | -3.6% | |
| Q3 2022 | +3.8% | +0.3% | +12.2% | |
| Q2 2022 | -9.7% | -14.4% | -16.5% | |
| Q1 2022 | +9.8% | +6.4% | +12.5% | |
| Q4 2021 | +8.8% | +7.6% | +12.1% | |
| Q3 2021 | -8.2% | -5.0% | -28.7% | |
| Q2 2021 | +5.9% | +11.6% | +28.9% | |
| Q1 2021 | -3.2% | -1.6% | +0.8% | |
| Q4 2020 | -11.8% | -13.7% | -15.3% | |
| Q3 2020 | +5.6% | +5.9% | +20.2% | |
| Q2 2020 | -8.8% | -7.4% | -19.0% | |
| Q1 2020 | -14.8% | -14.7% | +1.6% | |
| Q4 2019 | -7.0% | -7.8% | -15.5% | |
| Q3 2019 | +5.7% | +6.0% | +13.9% | |
| Q2 2019 | -10.2% | +1.2% | -12.3% | |
| Q1 2019 | -12.2% | -12.7% | -31.1% | |
| Q4 2018 | -1.2% | +3.6% | +3.3% | |
| Q3 2018 | +3.0% | +6.5% | -11.6% | |
| Q2 2018 | -0.1% | -0.3% | +2.0% | |
| Q1 2018 | +1.5% | +1.4% | +3.9% | |
| Q4 2017 | +16.6% | +23.0% | +12.0% | |
| Q3 2017 | +0.7% | -1.5% | +3.2% | |
| Q2 2017 | -4.1% | -5.4% | -12.4% | |
| Q1 2017 | +2.0% | +2.4% | +1.0% | |
| Q4 2016 | -2.9% | -4.6% | +3.7% | |
| Q3 2016 | -1.4% | +4.0% | +8.4% | |
| Q2 2016 | -3.6% | -6.0% | -14.1% | |
| Q1 2016 | -2.0% | — | — | |
| Q4 2015 | -1.4% | — | — | |
| Q3 2015 | +7.6% | — | — | |
| Q2 2015 | +2.4% | — | — | |
| Q1 2015 | +3.1% | — | — | |
| Q4 2014 | -3.4% | — | — | |
| Q3 2014 | +7.7% | — | — | |
| Q2 2014 | -7.2% | — | — | |
| Q1 2014 | +3.2% | — | — | |
| Q4 2013 | -7.7% | — | — | |
| Q3 2013 | -3.7% | — | — | |
| Q2 2013 | +3.5% | — | — | |
| Q1 2013 | +3.9% | — | — | |
| Q4 2010 | -1.0% | — | — | |
| Q4 2012 | -9.9% | — | — | |
| Q3 2012 | +2.2% | — | — | |
| Q3 2011 | +2.2% | — | — | |
| Q2 2011 | -7.7% | — | — | |
| Q2 2012 | -7.7% | — | — | |
| Q4 2011 | -7.7% | — | — | |
| Q2 2010 | -3.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro